Amphastar Pharmaceuticals, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/454a8eae-9d68-46c0-ba9e-e46cd2a5634c/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $140.4M | 2025-01-01 – 2025-12-31 | evidence 0001297184-26-000009 |
| FY 2024 | $205.4M | 2024-01-01 – 2024-12-31 | evidence 0001297184-25-000008 |
| FY 2023 | $197.0M | 2023-01-01 – 2023-12-31 | evidence 0001297184-24-000009 |
| FY 2022 | $107.5M | 2022-01-01 – 2022-12-31 | evidence 0001297184-23-000019 |
| FY 2021 | $69.9M | 2021-01-01 – 2021-12-31 | evidence 0001297184-22-000007 |
| FY 2020 | $11.0M | 2020-01-01 – 2020-12-31 | evidence 0001297184-21-000008 |
| FY 2019 | $-39.0k | 2019-01-01 – 2019-12-31 | evidence 0001297184-20-000007 |
| FY 2018 | $-8.6M | 2018-01-01 – 2018-12-31 | evidence 0001297184-19-000013 |
| FY 2017 | $-1.3M | 2017-01-01 – 2017-12-31 | evidence 0001297184-19-000013 |
| FY 2016 | $15.4M | 2016-01-01 – 2016-12-31 | evidence 0001297184-19-000013 |
| FY 2015 | $-6.9M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004146 |
| FY 2014 | $-18.0M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001654 |
| FY 2013 | $17.5M | 2013-01-01 – 2013-12-31 | evidence 0001171843-15-001654 |
| FY 2012 | $25.4M | 2012-01-01 – 2012-12-31 | evidence 0001171843-15-001654 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Amphastar Pharmaceuticals, Inc. — all facts · Revenue · Net Income